TLB-002

N/A

Report date: 2025/06/11 10:31:18
NME

Base Information

Drug NameTLB-002
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionCasein kinase I isoform delta inhibitorsCasein kinase I isoform epsilon inhibitorsTransforming growth factor beta 1 modulators
TargetsCasein kinase I isoform epsilonCasein kinase I isoform deltaTransforming growth factor beta 1
Therapy Area/IndicationsInflammationFibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTianli Biotech Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianli Biotech Pty Ltd
Inactive CompaniesN/A
Active IndicationsInflammationFibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A